Drugs that contain Neratinib Maleate

1. List of Nerlynx drug patents

NERLYNX's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7399865 PUMA BIOTECH Protein tyrosine kinase enzyme inhibitors
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7982043 PUMA BIOTECH Protein tyrosine kinase enzyme inhibitors
Oct, 2025

(2 years from now)

US9630946 PUMA BIOTECH Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
Oct, 2028

(5 years from now)

US9139558 PUMA BIOTECH Maleate salts of (E)-N-{4-[3-Chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
Oct, 2028

(5 years from now)

US10035788 PUMA BIOTECH Maleate salts of (E)-N-{4[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
Oct, 2028

(5 years from now)

US9265784 PUMA BIOTECH Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
Aug, 2029

(6 years from now)

US9211291 PUMA BIOTECH Treatment regimen utilizing neratinib for breast cancer
Mar, 2030

(6 years from now)

US8790708 PUMA BIOTECH Coated tablet formulations and uses thereof
Nov, 2030

(7 years from now)

US8518446 PUMA BIOTECH Coated tablet formulations and uses thereof
Nov, 2030

(7 years from now)

US8669273 PUMA BIOTECH Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
Jul, 2031

(8 years from now)

Do you want to check out NERLYNX patents from before 2022?
Exclusivity Exclusivity Expiration
New Indication (I) Feb 25, 2023
New Dosing Schedule (D) Jun 28, 2024

Market Authorisation Date: 17 July, 2017

Treatment: Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; Use in combination with capecitabine, for the tr...

Dosage: TABLET;ORAL

How can I launch a generic of NERLYNX before it's patent expiration?
More Information on Dosage

NERLYNX family patents

23

United States

19

Japan

14

China

13

Korea, Republic of

13

European Union

6

Spain

6

Russia

6

New Zealand

6

Israel

5

Hong Kong

5

Canada

5

Singapore

5

Argentina

5

Mexico

4

Brazil

4

Taiwan

4

Australia

2

Denmark

2

Poland

2

Croatia

2

Cyprus

2

Portugal

2

South Africa

2

Lithuania

2

Slovenia

2

Hungary

1

Panama

IB

1

IB

1

India

1

RS

1

San Marino

1

Chile

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic